CHINARES PHARMA reported the financial results for its subsidiary, Kpc Pharmaceuticals,Inc., for the three months ended March 31, 2026. The company recorded an operating revenue of 836 million yuan, representing a decrease of 48.01% compared to the same period last year. It reported a net loss of 145 million yuan, a significant swing from a profit of 114 million yuan in the prior-year period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments